Evidence map›Paper›PMID 25155358›Full record

ArticleNeuro-oncology2014

Human cytomegalovirus infection in tumor cells of the nervous system is not detectable with standardized pathologico-virological diagnostics.

Peter Baumgarten, Martin Michaelis, Florian Rothweiler, Tatjana Starzetz, Holger F Rabenau, Annemarie Berger, Lukas Jennewein, Anne K Braczynski, Kea Franz, Volker Seifert and 4 more

Open access · bronzeAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Peter BaumgartenNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Martin MichaelisNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Florian RothweilerNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Tatjana StarzetzNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Holger F RabenauNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Annemarie BergerNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Lukas JenneweinNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Anne K BraczynskiNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Kea FranzNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Volker SeifertNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Joachim P SteinbachNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Regina AllwinnNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Michel MittelbronnNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Jindrich CinatlNeurological Institute (Edinger Institute), Goethe University, Frankfurt am Main, Germany (P.B., T.S., L.J., A.K.B., Mi.M.); Institute of Medical Virology, Goethe University, Frankfurt am Main, Germany (Ma.M., F.R., H.F.R., A.B., R.A., J.C.); German Cancer Consortium, Heidelberg, Germany (J.P.S., Mi.M.); German Cancer Research Center, Heidelberg, Germany (J.P.S., Mi.M.); Department of Neurosurgery, Goethe University, Frankfurt am Main, Germany (K.F., V.S.); Senckenberg Institute of Neurooncology, University of Frankfurt am Main, Germany (K.F., J.P.S.).
Heidelberg University · DEDeutschen Konsortium für Translationale Krebsforschung · DEGoethe University Frankfurt · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundExperimental findings have suggested that human cytomegalovirus (HCMV) infection of tumor cells may exert oncomodulatory effects that enhance tumor malignancy. However, controversial findings have been published on the presence of HCMV in malignant tumors. Here, we present the first study that systematically investigates HCMV infection in human nervous system tumors by highly sensitive immunohistochemistry in correlation with the HCMV serostatus of the patients.

methodsImmunohistochemical and quantitative PCR-based methods to detect different HCMV antigens and genomic HCMV DNA were optimized prior to the investigation of pathological samples. Moreover, the pathological results were matched with the HCMV serostatus of the patients.

resultsHCMV immediate-early, late, and pp65 antigens could be detected in single cells from HCMV strain Hi91-infected UKF-NB-4 neuroblastoma cells after 1:1024 dilution with noninfected UKF-NB-4 cells. Genomic HCMV DNA could be detected in copy numbers as low as 430 copies/mL. However, we did not detect HCMV in tumors from a cohort of 123 glioblastoma, medulloblastoma, or neuroblastoma patients. Notably, we detected nonspecifically positive staining in tumor tissues of HCMV seropositive and seronegative glioblastoma patients. The HCMV serostatus of 67 glioblastoma patients matched the general epidemiological prevalence data for Western countries (72% of female and 57% of male glioblastoma patients were HCMV seropositive). Median survival was not significantly different in HCMV seropositive versus seronegative glioblastoma patients.

conclusionsThe prevalence of HCMV-infected tumor cells may be much lower than previously reported based on highly sensitive detection methods.

Indexed as

AdultAgedAged, 80 and overBlotting, WesternBrain NeoplasmsCase-Control StudiesCytomegalovirusCytomegalovirus InfectionsDNA, ViralFemaleFollow-Up StudiesGlioblastomaHumansImmunoenzyme TechniquesMaleMiddle AgedDNA, Viralcytomegalovirusgliomaoncomodulation

Identifiers

PMID25155358
PMCPMC4201076
OpenAlexW2152051481

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.